[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myocardial-revascularization\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myocardial-revascularization":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,60,77,110],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100638823","phase-3-clinical-study-of-chinese-herbal-compound-qidan-xiaoke-granules-in-patients-after-coronary-revascularization-100638823",false,"NCT07616544","Clinical Study of Chinese Herbal Compound Qidan Xiaoke Granules in Patients After Coronary Revascularization","Inclusion Criteria:\n\n1. Age: 18-80 years old;\n2. no gender limitation;\n3. Meets the diagnostic criteria for coronary heart disease;\n4. Accepts effective PCI procedure;\n5. Voluntarily participates and signs a written informed consent form.\n\nExclusion Criteria:\n\n1. Severe hepatic and\u002For renal insufficiency\n2. Severe electrolyte disorders\n3. Severe hematological diseases or malignant tumors\n4. Pregnant or breastfeeding women\n5. Patients with mental illness\n6. Cognitive impairment (e.g., dementia, post-stroke cognitive impairment) leading to inability to communicate normally\n7. Planning to undergo another revascularization surgery in the near future\n8. Other severe cardiovascular diseases (e.g., uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block without a pacemaker implanted, acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, acute aortic dissection, etc.)\n9. Acute pulmonary embolism and chronic lung diseases with dyspnea symptoms (occurring at rest or with minimal exertion)\n10. Explicit exclusion criteria (bleeding history within 1 month, active bleeding, bleeding tendency, currently using anticoagulants)\n11. Participants in other interventional clinical trials within the past month\n12. Allergy to known components of the investigational drug (Qidan Xiaohe Granules)\n13. Other conditions deemed unsuitable for participation in the trial by the investigator","ALL","18 Years","80 Years",{"count":19,"type":20},164,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","1. Evaluate the efficacy and safety of Qidan Xiaohe granules in patients after coronary revascularization surgery;\n2. Develop a traditional Chinese medicine rehabilitation treatment plan and evaluation system for the use of Qidan Xiaohe granules after coronary revascularization surgery;\n3. Demonstrate the advantages of traditional Chinese medicine rehabilitation treatment in the postoperative management of coronary revascularization surgery and provide high-level evidence-based medical evidence for the development of traditional Chinese medicine rehabilitation treatment plans.",[26,27,28],"Percutaneous Coronary Intervention","Myocardial Revascularization","Coronary Artery Disease","NOT_YET_RECRUITING","2026-05-27",{"date":32,"type":33},"2026-06-01","ACTUAL",{"date":35,"type":20},"2026-07-01",{"date":37,"type":20},"2028-12-31",{"name":39,"class":40},"Liu Qiang","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":50,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":57,"completionDateStruct":58,"leadSponsor":59,"locationsCount":4},"100639444","establishment-of-disease-characteristics-and-a-chinese-medicine-prognosis-risk-model-based-on-a-large-scale-database-after-coronary-revascularization-100639444","NCT07613060","Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization","Inclusion Criteria:\n\n* Diagnosis of coronary artery disease with prior coronary revascularization (PCI or CABG)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Malignant arrhythmias, severe heart failure, myocardial disease, or structural heart disease\n* Severe pulmonary insufficiency, severe liver or kidney dysfunction, severe electrolyte disturbances\n* Pregnancy or breastfeeding\n* Severe psychiatric disorders, malignant tumors, hematologic diseases, rheumatic immune diseases, or severe infection\n* Poor compliance or any other reason making the participant unsuitable for the study",{"count":48,"type":20},600,"12 Months","OBSERVATIONAL","This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.",[28,53,27],"Postoperative Period","2026-05-21",{"date":56,"type":33},"2026-05-29",{"date":35,"type":20},{"date":37,"type":20},{"name":39,"class":40},{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":70,"conditions":71,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":75,"leadSponsor":76,"locationsCount":4},"100639118","baduanjin-intervention-in-clinical-studies-after-coronary-revascularization-surgery-100639118","NCT07607951","Baduanjin Intervention in Clinical Studies After Coronary Revascularization Surgery","Inclusion Criteria:\n\n* Participants who meet the diagnostic criteria for coronary heart disease\n* Participants who underwent successful percutaneous coronary intervention\n* Participants aged between 18 and 80\n* Participants of any gender\n* Participants who have signed an informed consent form\n\nExclusion Criteria:\n\n* Subjects with severe hepatic or renal impairment\n* subjects with severe electrolyte disturbances\n* subjects with severe haematological disorders or malignant tumours\n* pregnant or breastfeeding women\n* subjects with psychiatric disorders\n* subjects with cognitive impairment (e.g. dementia, post-stroke cognitive impairment) that prevents them from understanding or carrying out exercise instructions\n* Subjects scheduled to undergo repeat revascularisation surgery in the near future\n* Subjects with other severe cardiovascular diseases such as uncontrolled hypertension, angina pectoris, rapid arrhythmias, high-degree or complete atrioventricular block (without a pacemaker), acute severe aortic stenosis, decompensated heart failure (NYHA Class IV), deep vein thrombosis, obstructive hypertrophic cardiomyopathy, acute pericarditis or myocarditis, acute endocarditis, or acute aortic dissection\n* Participants with acute pulmonary embolism or chronic lung disease accompanied by symptoms of dyspnoea (occurring at rest or with minimal exertion)\n* Subjects with impaired limb mobility or who are unable to move independently;\n* Subjects with Shy-Drager syndrome\n* Subjects who have participated in a clinical trial involving other drugs or exercise interventions within the past month\n* Subjects deemed by the investigator to have other conditions rendering them unsuitable for participation in the trial",{"count":67,"type":20},310,[69],"NA","1. To evaluate the efficacy and safety of the Baduanjin exercise programme in patients following coronary revascularisation surgery;\n2. To develop a traditional Chinese medicine (TCM) rehabilitation protocol and evaluation system for patients following coronary revascularisation surgery;\n3. To clarify the advantages of TCM rehabilitation in the post-operative management of coronary revascularisation surgery and to provide high-level evidence-based medical evidence for TCM rehabilitation protocols.",[26,27,28],"2026-05-19",{"date":30,"type":33},{"date":35,"type":20},{"date":37,"type":20},{"name":39,"class":40},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100639783","nursing-intervention-for-adaptation-after-myocardial-revascularization-100639783","NCT07576569","Nursing Intervention for Adaptation After Myocardial Revascularization","Preliminary Effectiveness of a Nursing Intervention Aimed at Improving Adaptation in Patients and Their Caregivers During the Outpatient Postoperative Period Following Myocardial Revascularization","ADAPT-CABG","Inclusion Criteria:\n\n* Adults aged 18 years or older who have undergone myocardial revascularization surgery, completed the immediate postoperative in-hospital period without major complications, and have been discharged for outpatient management according to institutional protocols\n* Patients who, at the time of discharge, do not require ventilatory support, invasive hemodynamic support, or continuous monitoring, and present documented clinical stability\n* Presence of an identified primary caregiver actively involved in the home care process during the outpatient postoperative period\n* Preserved cognitive capacity in both patient and caregiver, allowing understanding of instructions, participation in the intervention, and completion of assessment instruments\n* Written informed consent provided by both patient and caregiver\n\nExclusion Criteria:\n\n* Patients presenting severe postoperative complications, such as deep surgical site infection, persistent hemodynamic instability, major neurological events, or readmission to the intensive care unit at the start of the intervention Patients with moderate to severe cognitive impairment, decompensated psychiatric disorders, or neurological conditions that limit understanding, communication, or active participation\n* Caregivers with physical, cognitive, or emotional limitations that compromise the effective performance of the caregiving role during the follow-up period\n* Patients without a clearly identified support network or without an available primary caregiver to participate in the study\n* Concurrent participation in other clinical, educational, or psychosocial intervention studies that may interfere with the proposed intervention\n* Language or cultural barriers that prevent understanding of the intervention content or interaction with the research team, without adequate mediation",{"count":86,"type":20},40,[69],"Introduction: Myocardial revascularization is an essential procedure for patients with cardiovascular disease. Its recovery in the outpatient setting involves significant challenges for both the patient and the caregiver. This recovery phase may generate physical, emotional, and psychological complications that require an effective adaptation process of the patient-caregiver dyad to ensure successful recovery and improved quality of life.\n\nObjective: To evaluate the preliminary effectiveness of a nursing intervention aimed at improving adaptation in the patient-caregiver dyad during the outpatient postoperative period following myocardial revascularization, compared with usual care, in Bucaramanga during the period 2026-2027.\n\nMaterials and Methods: A pilot randomized controlled trial will be conducted to develop and evaluate a novel nursing intervention aimed at promoting adaptation in patients undergoing outpatient postoperative myocardial revascularization and their caregivers. The intervention will be designed and its feasibility, acceptability, and preliminary effectiveness will be assessed. Data analysis will be performed using descriptive and inferential statistical methods, considering the distribution and behavior of the data.\n\nExpected Results: The study is expected to assess the preliminary effectiveness of the proposed intervention through the integration of theoretical and empirical components.",[28,27,90,91],"Postoperative Recovery After Cardiac Surgery","Nursing Care",[27,93,94,95,96,97,98,99],"Nursing Intervention","Patient-Caregiver Dyad","Adaptation","Postoperative Recovery","Cardiovascular Disease","Randomized Controlled Trial","Outpatient Care","2026-05-02",{"date":102,"type":33},"2026-05-08",{"date":104,"type":20},"2027-01",{"date":106,"type":20},"2027-12",{"name":108,"class":40},"Universidad de la Sabana",1,{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":50,"phases":4,"briefSummary":119,"conditions":120,"keywords":125,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":4},"100611387","disease-characteristics-of-r-cad-100611387","NCT07239921","Disease Characteristics of R-CAD","Disease Characteristics of Rapidly Progressive Coronary Artery Disease (R-CAD): A Case-control Study","Inclusion Criteria:\n\nCase Group (R-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or CABG).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest coronary revascularization.\n5. Rapidly progressive myocardial ischemia leading to hospitalization and\u002For coronary revascularization:\n\n   1. Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] classification III-IV) and non-invasive evidence of myocardial ischemia; and\n   2. Occurred within 6 months of the latest ischemia-driven hospitalization and\u002For coronary revascularization.\n6. Rapidly progressive coronary lesions leading to myocardial ischemia:\n\n   1. Angiographic evidence of new-onset or worsened coronary de novo or restenotic lesions relevant to myocardial ischemia, and\n   2. Occurred within 6 months of the latest ischemia-driven coronary angiography and\u002For revascularization.\n\nControl Group (NR-CAD patients):\n\n1. 35 to 75 years old\\*, male or female. (\\* Based on the age distribution characteristics of patients who have been diagnosed as R-CAD.)\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, at 12±6 months after the latest PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the latest PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the index hospitalization.\n6. No evidence of rapidly progressive myocardial ischemia and coronary lesions, i.e., not fulfilling items 5) and 6) of the inclusion criteria for R-CAD.\n\nExclusion Criteria:\n\n1. Receiving immunosuppressive therapy within 6 months.\n2. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n3. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n8. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n9. Previous enrollment in this study.\n10. Participation in another study within 30 days.\n11. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n12. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":118,"type":20},52,"The present case-control study is designed to investigate the disease characteristics of rapidly progressive coronary artery disease (R-CAD) by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between patients in the case group (approximately 34 patients with R-CAD) and those in the control group (approximately 18 patients with non-rapidly progressive coronary artery disease \\[NR-CAD\\]).",[28,121,122,123,124,27,26],"Coronary Artery Disease Progression","Coronary Stenosis","Coronary Restenosis","Coronary Stent Occlusion",[28,122,123,27,26,126,127],"Disease Progression","Disease Attributes","2025-11-21",{"date":130,"type":33},"2025-11-28",{"date":132,"type":20},"2025-11",{"date":134,"type":20},"2026-10",{"name":136,"class":40},"Peking Union Medical College Hospital"]